Trials / Recruiting
RecruitingNCT05906862
AMT-253 in Patients With Selected Advanced Solid Tumours
First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Multitude Therapeutics (Australia) Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-253 | Administered intravenously |
Timeline
- Start date
- 2023-11-06
- Primary completion
- 2026-09-30
- Completion
- 2026-12-30
- First posted
- 2023-06-18
- Last updated
- 2025-08-14
Locations
7 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05906862. Inclusion in this directory is not an endorsement.